Go Pro
→ 3 Signs of The Biggest “Melt-Up” in U.S. History (From True Market Insiders) (Ad)tc pixel Free AIFF Stock Alerts

Firefly Neuroscience (AIFF) Financials

Firefly Neuroscience logo
$1.10 -0.08 (-6.36%)
Closing price 04:00 PM Eastern
Extended Trading
$1.10 0.00 (0.00%)
As of 05:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Firefly Neuroscience

Annual Income Statements for Firefly Neuroscience

This table shows Firefly Neuroscience's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 0.08 -0.55 0.25 -0.05 -0.72 0.41 -1.13 -18 -2.60 -10 -25
Consolidated Net Income / (Loss)		 0.08 -0.55 0.25 -0.05 -0.72 0.41 -1.13 -18 -2.60 -10 -20
Net Income / (Loss) Continuing Operations		 0.08 -0.55 0.25 -0.05 -0.72 0.41 -1.13 -6.31 -2.60 -10 -20
Total Pre-Tax Income 		0.08 -0.55 0.25 -0.05 -0.72 0.41 -2.20 -5.49 -2.60 -10 -20
Total Operating Income		 0.07 -0.56 0.24 -0.06 -0.73 0.41 -2.63 -5.42 -3.08 -10 -8.86
Total Gross Profit		 2.37 1.82 2.42 2.14 1.40 2.21 3.62 2.86 0.50 0.11 0.65
Total Revenue		 6.21 6.73 11 8.93 10 14 15 11 0.50 0.11 1.14
Operating Revenue		 6.21 6.73 11 8.93 10 14 15 11 0.50 0.11 1.14
Total Cost of Revenue		 3.84 4.91 8.23 6.79 8.77 12 11 8.16 0.00 0.00 0.50
Operating Cost of Revenue		 3.84 4.91 8.23 6.79 8.77 12 11 8.16 - 0.00 0.50
Total Operating Expenses		 2.30 2.39 2.18 2.21 2.13 1.80 6.24 8.28 3.58 10 9.50
Selling, General & Admin Expense		 2.30 2.39 2.18 2.21 2.13 1.80 6.24 8.28 2.20 6.13 6.97
Marketing Expense		 - - - - - - - - 0.64 1.20 0.80
Research & Development Expense		 - - - - - - - - 0.74 1.95 1.48
Impairment Charge		 - - - - - - 0.00 - 0.00 0.87 0.25
Total Other Income / (Expense), net		 0.01 0.01 0.01 0.01 0.01 0.00 0.42 -0.07 0.48 -0.40 -11
Interest Expense		 - - - - - 0.00 -0.41 0.08 - 0.00 1.35
Interest & Investment Income		 - - - - - - - 0.00 - 0.00 -0.07
Other Income / (Expense), net		 0.01 0.01 0.01 0.01 0.01 0.00 0.01 0.01 0.46 -0.35 -9.60
Income Tax Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -1.07 0.81 0.00 -0.00 0.01
Preferred Stock Dividends Declared		 - - - - - - - - - - 4.65
Basic Earnings per Share		 $0.01 ($0.05) $0.02 $0.00 ($0.06) $0.04 ($0.09) ($10.03) ($0.81) ($1.60) ($1.97)
Weighted Average Basic Shares Outstanding		 11.20M 11.20M 11.20M 11.20M 11.21M 11.22M 12.57M 1.77M 3.23M 6.55M 12.44M
Weighted Average Diluted Shares Outstanding		 11.31M 11.20M 11.58M 11.20M 11.21M 12.05M - 19.26M 2.01M 11.62M 14.79M
Weighted Average Basic & Diluted Shares Outstanding		 11.20M 11.20M 11.20M 11.20M 11.21M 11.29M - 19.26M 2.01M 11.62M 14.79M

Quarterly Income Statements for Firefly Neuroscience

This table shows Firefly Neuroscience's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -0.65 -0.84 -1.12 -1.26 -4.29 -3.79 -17 -1.83 -2.64 -2.72 -2.09
Consolidated Net Income / (Loss)		 -0.65 -0.84 -1.12 -1.26 -4.29 -3.79 -13 -1.83 -2.64 -2.48 -2.00
Net Income / (Loss) Continuing Operations		 -0.65 -0.94 -1.12 -1.26 -4.29 -3.78 -13 -1.83 -2.64 -2.48 -2.00
Total Pre-Tax Income 		-0.65 -1.42 -1.12 -1.26 -4.29 -3.78 -13 -1.83 -2.64 -2.48 -2.00
Total Operating Income		 -0.65 -1.97 -1.09 -1.26 -4.27 -3.44 -2.07 -1.63 -2.66 -2.50 -2.01
Total Gross Profit		 0.02 -0.89 0.01 0.01 0.03 0.05 0.04 0.27 0.15 0.18 0.22
Total Revenue		 0.02 -3.71 0.01 0.01 0.03 0.05 0.04 0.30 0.39 0.41 0.49
Operating Revenue		 0.02 -3.71 0.01 0.01 0.03 0.05 0.04 0.30 0.39 0.41 0.49
Total Cost of Revenue		 0.00 -2.82 0.00 0.00 0.00 - 0.00 0.03 0.24 0.23 0.26
Operating Cost of Revenue		 - - - 0.00 0.00 - 0.00 0.03 0.24 - 0.26
Total Operating Expenses		 0.67 1.08 1.10 1.27 4.30 3.49 2.11 1.91 2.80 2.68 2.23
Selling, General & Admin Expense		 0.18 -1.25 0.57 0.63 2.99 1.95 1.59 1.37 2.01 2.00 1.67
Marketing Expense		 0.10 - 0.25 0.29 0.43 0.23 0.21 0.20 0.27 0.13 0.14
Research & Development Expense		 0.39 - 0.29 0.35 0.88 0.44 0.31 0.34 0.38 0.46 0.42
Total Other Income / (Expense), net		 0.00 0.55 -0.03 -0.01 -0.02 -0.35 -11 -0.19 0.02 0.02 0.01
Interest Expense		 - - 0.00 0.00 0.00 - 1.35 0.00 0.00 - 0.00
Interest & Investment Income		 - - -0.00 -0.01 -0.02 0.04 -0.13 0.02 0.02 0.02 0.01
Other Income / (Expense), net		 0.00 0.46 -0.03 0.01 0.01 -0.33 -9.38 -0.20 -0.00 -0.01 -0.00
Income Tax Expense		 0.00 0.00 0.00 0.00 0.00 -0.00 0.00 0.00 0.00 0.00 0.00
Preferred Stock Dividends Declared		 - - 0.00 0.00 0.00 - 4.41 0.00 0.00 0.24 0.09
Basic Earnings per Share		 ($0.18) ($0.26) ($0.22) ($0.24) ($0.61) ($0.58) ($1.74) ($0.14) ($0.20) ($0.22) ($0.13)
Weighted Average Basic Shares Outstanding		 3.68M 3.23M 5.19M 5.19M 7.08M 6.55M 9.96M 12.67M 13.50M 12.44M 16.23M
Weighted Average Diluted Shares Outstanding		 2.01M 2.01M 2.01M 7.34M 7.08M 11.62M 12.86M 13.39M 13.50M 14.79M 15.57M
Weighted Average Basic & Diluted Shares Outstanding		 2.01M 2.01M 2.01M 7.34M 8.50M 11.62M 12.86M 13.39M - 14.79M 15.57M

Annual Cash Flow Statements for Firefly Neuroscience

This table details how cash moves in and out of Firefly Neuroscience's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -0.28 -0.27 0.84 -0.77 -0.92 0.82 3.07 -4.20 2.09 -0.33 0.94
Net Cash From Operating Activities		 -0.26 -0.26 0.84 -0.76 -0.92 0.42 -0.74 -6.01 -2.17 -6.16 -8.19
Net Cash From Continuing Operating Activities		 0.19 -0.19 -0.56 -0.76 -0.92 0.42 0.51 -7.68 -2.17 -6.16 -8.19
Net Income / (Loss) Continuing Operations		 0.08 -0.55 0.25 -0.05 -0.72 0.41 -1.13 -6.31 -2.60 -10 -20
Consolidated Net Income / (Loss)		 0.08 -0.55 0.25 -0.05 -0.72 0.41 -1.13 -18 -2.60 -10 -20
Depreciation Expense		 0.03 0.03 0.02 0.01 0.01 0.01 0.24 0.22 0.00 0.07 0.17
Amortization Expense		 - - - - - - 0.62 0.18 - 0.00 0.13
Non-Cash Adjustments To Reconcile Net Income		 0.02 0.02 0.02 -0.04 0.15 0.30 1.63 1.36 0.30 3.64 3.20
Changes in Operating Assets and Liabilities, net		 -0.39 0.25 0.56 -0.68 -0.36 -0.30 -0.85 -3.14 0.14 0.60 8.19
Net Cash From Investing Activities		 -0.02 -0.02 0.00 -0.00 -0.01 -0.06 -9.58 -0.54 -0.39 -0.48 -2.49
Net Cash From Continuing Investing Activities		 -0.02 -0.02 0.00 -0.00 -0.01 -0.06 -9.58 -0.54 -0.39 -0.48 -2.49
Purchase of Property, Plant & Equipment		 -0.02 -0.01 -0.00 -0.01 -0.01 -0.06 -0.07 -0.54 0.00 -0.15 -0.13
Acquisitions		 - - - - - 0.00 -9.51 - 0.00 -0.06 -2.36
Other Investing Activities, net		 0.00 -0.01 -0.00 - - - - 0.00 -0.39 -0.27 0.00
Net Cash From Financing Activities		 0.00 0.00 0.00 0.00 0.00 0.46 13 2.35 4.64 6.30 12
Net Cash From Continuing Financing Activities		 0.00 0.00 0.00 0.00 0.00 0.46 13 2.35 4.64 6.30 12
Issuance of Debt		 - - - - 0.00 0.45 1.60 0.43 0.00 1.96 2.53
Other Financing Activities, net		 - - - 0.00 0.00 0.01 0.10 0.04 4.64 4.34 9.09
Cash Interest Paid		 0.00 0.00 0.00 0.00 - 0.00 0.04 0.00 0.00 0.01 0.00
Cash Income Taxes Paid		 0.00 0.00 0.00 0.01 - - - - 0.00 0.00 0.00

Quarterly Cash Flow Statements for Firefly Neuroscience

This table details how cash moves in and out of Firefly Neuroscience's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 1.23 1.25 -0.51 -1.28 0.87 0.58 7.74 -3.63 -1.59 -1.58 0.38
Net Cash From Operating Activities		 0.49 -0.51 -1.32 -1.10 -2.52 -1.22 -2.51 -2.39 -1.49 -1.81 -1.95
Net Cash From Continuing Operating Activities		 -0.20 -0.51 -1.32 -1.10 -2.52 -1.22 -2.51 -2.39 -1.49 -1.81 -1.95
Net Income / (Loss) Continuing Operations		 -0.75 -1.08 -1.12 -1.26 -4.29 -3.79 -13 -1.83 -2.64 -2.48 -2.00
Consolidated Net Income / (Loss)		 -0.41 -1.08 -1.12 -1.26 -4.29 -3.79 -13 -1.83 -2.64 -2.48 -2.00
Depreciation Expense		 -0.11 - 0.00 0.00 0.00 0.06 0.02 0.04 0.06 0.05 0.05
Amortization Expense		 - - 0.00 - - - 0.13 - - - 0.00
Non-Cash Adjustments To Reconcile Net Income		 1.02 0.07 0.06 0.06 2.53 1.00 1.70 0.37 0.83 0.31 0.58
Changes in Operating Assets and Liabilities, net		 -0.30 0.50 -0.26 0.10 -0.76 1.51 8.58 -0.97 0.27 0.31 -0.57
Net Cash From Investing Activities		 -0.94 -0.39 -0.13 -0.18 -0.09 -0.08 -0.01 -2.37 -0.09 -0.02 -0.06
Net Cash From Continuing Investing Activities		 -0.94 -0.39 -0.13 -0.18 -0.09 -0.08 -0.01 -2.37 -0.09 -0.02 -0.06
Purchase of Property, Plant & Equipment		 - - 0.00 -0.06 -0.00 -0.08 -0.01 -0.01 -0.09 -0.02 -0.06
Net Cash From Financing Activities		 1.67 2.15 0.95 - 3.48 1.87 10 1.14 -0.02 0.25 2.39
Net Cash From Continuing Financing Activities		 1.67 2.15 0.95 - 3.48 1.87 10 1.14 -0.02 0.25 2.39
Other Financing Activities, net		 2.18 2.15 0.95 - 3.48 -0.08 10 1.14 -2.55 0.25 2.39

Annual Balance Sheets for Firefly Neuroscience

This table presents Firefly Neuroscience's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 4.12 3.75 3.73 3.02 2.37 3.77 23 7.98 2.64 4.60 10
Total Current Assets		 4.07 3.72 3.72 3.01 2.21 3.44 6.87 2.80 2.26 2.63 4.03
Cash & Equivalents		 2.17 1.90 2.73 1.96 1.04 1.86 4.93 0.73 2.14 1.81 2.75
Accounts Receivable		 1.30 1.16 0.61 0.65 0.67 1.44 1.66 1.63 0.08 0.12 0.19
Inventories, net		 - - - - - - - - - 0.00 0.11
Prepaid Expenses		 0.60 0.66 0.37 0.39 0.50 0.14 0.28 0.44 0.03 0.70 0.98
Plant, Property, & Equipment, net		 0.04 0.03 0.01 0.01 0.01 0.06 0.11 0.10 0.00 0.14 0.15
Total Noncurrent Assets		 0.01 0.01 0.01 0.01 0.16 0.27 16 5.08 0.39 1.84 6.30
Goodwill		 - - - - - 0.00 7.59 1.13 - 0.00 5.18
Intangible Assets		 - - - - - 0.00 8.05 1.18 0.39 0.18 0.86
Other Noncurrent Operating Assets		 0.01 0.01 0.01 0.01 0.16 0.27 0.75 2.77 0.00 1.66 0.27
Total Liabilities & Shareholders' Equity		 4.12 3.75 3.73 3.02 2.37 3.77 23 7.98 2.64 4.60 10
Total Liabilities		 1.94 2.12 1.84 1.15 1.21 2.16 5.92 4.25 2.53 4.98 2.84
Total Current Liabilities		 1.94 2.12 1.84 1.15 1.17 1.80 1.98 3.89 2.53 4.98 2.82
Short-Term Debt		 - - - - 0.00 0.09 0.00 0.43 0.00 0.69 0.48
Accounts Payable		 0.06 0.05 0.05 0.03 0.22 0.10 0.65 0.57 0.63 1.82 1.35
Accrued Expenses		 1.03 1.25 1.12 0.59 0.16 0.24 0.43 0.41 1.90 1.63 0.77
Current Deferred Revenue		 0.58 0.62 - - - - - - 0.00 0.01 0.23
Total Noncurrent Liabilities		 0.00 0.00 0.00 0.00 0.05 0.36 3.94 0.36 0.00 0.00 0.02
Noncurrent Deferred Revenue		 - - - - - - - - - 0.00 0.02
Commitments & Contingencies		 - - - - - - - - 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 2.18 1.63 1.89 1.87 1.16 1.61 17 3.73 0.11 -0.38 7.64
Total Preferred & Common Equity		 2.18 1.63 1.89 1.87 1.16 1.61 17 3.73 0.11 -0.38 7.64
Preferred Stock		 - - - - - - - - 0.00 0.00 0.00
Total Common Equity		 2.18 1.63 1.89 1.87 1.16 1.61 17 3.73 0.11 -0.38 7.64
Common Stock		 15 15 15 15 15 15 32 36 77 87 119
Retained Earnings		 -12 -12 -12 -12 -13 -12 -13 -31 -77 -87 -112

Quarterly Balance Sheets for Firefly Neuroscience

This table presents Firefly Neuroscience's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 5.26 3.76 3.31 5.31 12 15 12 11
Total Current Assets		 2.72 1.56 1.17 2.67 10 7.53 5.43 4.46
Cash & Equivalents		 0.88 0.56 0.24 1.23 9.55 5.92 4.33 3.13
Accounts Receivable		 1.48 0.78 0.79 0.09 0.10 0.20 0.18 0.19
Inventories, net		 - - - - - 0.13 0.08 0.10
Prepaid Expenses		 0.36 0.22 0.13 1.35 0.73 1.28 0.84 1.04
Plant, Property, & Equipment, net		 0.07 0.05 0.04 0.07 0.13 0.14 0.24 0.20
Total Noncurrent Assets		 2.47 2.16 2.10 2.57 1.85 7.27 6.74 6.25
Goodwill		 1.13 1.13 1.13 - - 5.18 5.18 5.18
Intangible Assets		 1.05 0.96 0.93 1.11 0.17 1.10 0.90 0.82
Other Noncurrent Operating Assets		 0.30 0.07 0.05 1.47 1.68 1.00 0.67 0.25
Total Liabilities & Shareholders' Equity		 5.26 3.76 3.31 5.31 12 15 12 11
Total Liabilities		 2.38 2.06 1.93 2.54 7.18 2.84 2.75 2.47
Total Current Liabilities		 2.18 2.04 1.91 2.54 7.18 2.80 2.72 2.45
Short-Term Debt		 0.59 0.50 0.30 - 0.00 0.48 0.00 0.48
Accounts Payable		 0.50 0.66 0.76 1.38 1.61 1.50 1.35 1.33
Accrued Expenses		 0.24 0.17 0.23 1.15 1.16 0.53 0.66 0.45
Other Current Liabilities		 0.22 0.08 0.04 - 4.41 0.00 0.48 0.19
Total Noncurrent Liabilities		 0.19 0.02 0.02 0.00 0.00 0.04 0.03 0.01
Noncurrent Deferred Revenue		 - - - - - 0.04 0.03 0.01
Commitments & Contingencies		 - - - 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 2.88 1.71 1.38 2.78 5.19 12 9.66 8.44
Total Preferred & Common Equity		 2.88 1.71 1.38 2.78 5.19 12 9.66 8.44
Preferred Stock		 - - - 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 2.88 1.71 1.38 2.78 5.19 12 9.66 8.44
Common Stock		 36 37 37 86 110 118 119 122
Retained Earnings		 -32 -34 -34 -83 -104 -106 -109 -114

Annual Metrics And Ratios for Firefly Neuroscience

This table displays calculated financial ratios and metrics derived from Firefly Neuroscience's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 11,201,760.00 11,201,760.00 11,201,760.00 11,201,760.00 11,211,760.00 11,261,760.00 13,510,690.00 19,165,548.00 2,013,180.00 8,503,365.00 13,392,918.00
DEI Adjusted Shares Outstanding		 3,733,920.00 3,733,920.00 3,733,920.00 3,733,920.00 3,737,253.00 3,753,920.00 4,503,563.00 6,388,516.00 671,060.00 8,503,365.00 13,392,918.00
DEI Earnings Per Adjusted Shares Outstanding		 0.02 -0.15 0.07 -0.01 -0.19 0.11 -0.25 -2.78 -3.88 -1.23 -1.83
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 7.45% 8.27% 58.14% -16.04% 13.78% 36.77% 8.13% -26.68% -95.48% -78.31% 957.41%
EBITDA Growth		 6,709.06% -585.62% 150.12% -115.67% -1,623.51% 160.24% -509.95% -185.09% 47.67% -294.24% -75.71%
EBIT Growth		 362.97% -806.86% 144.51% -120.71% -1,305.43% 158.07% -727.84% -106.96% 51.57% -296.80% -77.44%
NOPAT Growth		 344.32% -678.97% 160.28% -118.35% -1,067.35% 180.84% -546.53% -106.27% 43.20% -226.64% 11.92%
Net Income Growth		 362.97% -806.86% 144.51% -120.71% -1,305.43% 157.63% -373.71% -1,469.12% 85.34% -301.84% -90.08%
EPS Growth		 0.00% -600.00% 140.00% -100.00% 0.00% 150.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Growth		 -327.10% 3.20% 425.94% -191.32% -20.12% 146.15% -273.65% -718.21% 63.88% -183.38% -33.13%
Free Cash Flow Firm Growth		 -484.63% 59.33% 764.26% -197.21% 8.36% 145.10% -4,431.82% 137.43% -37.59% -329.50% -72.25%
Invested Capital Growth		 102.58% -2,937.97% -218.61% 89.09% 234.55% 69.48% 5,904.31% -72.63% -159.41% 26.70% 460.03%
Revenue Q/Q Growth		 -3.90% -7.73% 9.97% -9.69% -22.89% 51.14% -3.33% -9.66% -91.94% 102.96% 45.85%
EBITDA Q/Q Growth		 330.25% -1,826.18% 462.10% -152.28% -16.21% 659.61% -340.90% 21.71% -27.01% -26.92% 7.03%
EBIT Q/Q Growth		 201.49% -876.29% 813.84% -175.18% -15.96% 591.03% -526.63% 26.79% -23.76% -27.61% 6.36%
NOPAT Q/Q Growth		 211.64% -746.17% 1,213.23% -176.42% -15.60% 768.54% -407.74% 26.74% -45.11% -17.08% 9.55%
Net Income Q/Q Growth		 201.49% -876.29% 813.84% -175.18% -15.96% 587.34% -295.73% -83.90% 76.79% -39.23% 6.16%
EPS Q/Q Growth		 200.00% 0.00% 100.00% 0.00% 0.00% 200.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 -180.60% -157.66% 439.75% -54.37% 3.65% 2,967.07% -1,687.75% -11.18% 15.67% -13.00% -7.72%
Free Cash Flow Firm Q/Q Growth		 -195.54% -128.89% 408.92% -46.22% 8.88% 654.22% -412.15% 141.60% -52.96% -52.97% -22.73%
Invested Capital Q/Q Growth		 101.67% 74.36% -12.54% 37.84% -40.50% 2.17% 251.15% -69.18% -178.19% -196.44% 0.68%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 38.18% 27.09% 22.70% 23.99% 13.77% 15.89% 24.05% 25.97% 100.00% 100.00% 56.48%
EBITDA Margin		 1.74% -7.81% 2.48% -0.46% -7.00% 3.08% -11.69% -45.44% -526.31% -9,567.59% -1,589.84%
Operating Margin		 1.10% -8.37% 2.23% -0.70% -7.16% 2.96% -17.48% -49.16% -618.07% -9,309.26% -775.48%
EBIT Margin		 1.26% -8.23% 2.32% -0.57% -7.06% 3.00% -17.39% -49.10% -526.31% -9,629.63% -1,615.94%
Profit (Net Income) Margin		 1.26% -8.23% 2.32% -0.57% -7.06% 2.97% -7.53% -161.06% -522.69% -9,685.19% -1,740.98%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 51.38% 323.18% 100.04% 100.02% 100.03%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 99.25% 84.22% 101.51% 99.28% 100.56% 107.71%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% -3,227.54% 248.64% -28.92% -47.61% -310.05% 0.00% -319.79%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% -3,213.70% 248.51% -51.25% 485.50% -273.44% 0.00% 488.64%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 3,180.27% -218.85% 17.04% -120.10% 174.44% 0.00% -227.77%
Return on Equity (ROE)		 3.67% -29.07% 13.98% -2.71% -47.27% 29.78% -11.88% -167.72% -135.61% 7,864.66% -547.56%
Cash Return on Invested Capital (CROIC)		 -3,247.13% 0.00% 0.00% 0.00% -588.73% 197.07% -222.37% 66.44% 0.00% 0.00% -243.26%
Operating Return on Assets (OROA)		 1.87% -14.07% 6.58% -1.51% -26.58% 13.55% -19.27% -34.53% -49.35% -287.21% -244.78%
Return on Assets (ROA)		 1.87% -14.07% 6.58% -1.51% -26.58% 13.45% -8.34% -113.28% -49.01% -288.87% -263.72%
Return on Common Equity (ROCE)		 3.67% -29.07% 13.98% -2.71% -47.27% 29.78% -11.88% -167.72% -135.61% 7,864.66% -547.56%
Return on Equity Simple (ROE_SIMPLE)		 3.60% -33.92% 13.01% -2.73% -61.71% 25.62% -6.49% -475.99% -2,388.07% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 0.07 -0.39 0.24 -0.04 -0.51 0.41 -1.84 -3.79 -2.15 -7.04 -6.20
NOPAT Margin		 1.10% -5.86% 2.23% -0.49% -5.01% 2.96% -12.23% -34.41% -432.65% -6,516.48% -542.84%
Net Nonoperating Expense Percent (NNEP)		 0.44% -7.84% 0.38% -0.31% -13.84% 0.13% 22.33% -533.11% -36.62% -210.02% -808.44%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -1,976.70% -2,206.21% -76.39%
Cost of Revenue to Revenue		 61.82% 72.91% 77.30% 76.01% 86.23% 84.11% 75.95% 74.03% 0.00% 0.00% 43.52%
SG&A Expenses to Revenue		 37.08% 35.46% 20.47% 24.68% 20.93% 12.93% 41.53% 75.13% 440.96% 5,678.70% 610.16%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 148.80% 1,809.26% 129.77%
Operating Expenses to Revenue		 37.08% 35.46% 20.47% 24.68% 20.93% 12.93% 41.53% 75.13% 718.07% 9,409.26% 831.96%
Earnings before Interest and Taxes (EBIT)		 0.08 -0.55 0.25 -0.05 -0.72 0.42 -2.61 -5.41 -2.62 -10 -18
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 0.11 -0.53 0.26 -0.04 -0.71 0.43 -1.76 -5.01 -2.62 -10 -18
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 6.69 8.23 24.84 8.67 12.76 101.21 38.34 24.66 31.21 0.00 1.53
Price to Tangible Book Value (P/TBV)		 6.69 8.23 24.84 8.67 12.76 101.21 370.12 64.63 0.00 0.00 7.32
Price to Revenue (P/Rev)		 2.34 2.00 4.42 1.82 1.46 11.75 44.49 8.34 6.83 208.65 10.26
Price to Earnings (P/E)		 185.91 0.00 190.89 0.00 0.00 395.03 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.54% 0.00% 0.52% 0.00% 0.00% 0.25% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 1,338.19 0.00 0.00 0.00 112.20 777.00 53.07 26.77 0.00 0.00 1.76
Enterprise Value to Revenue (EV/Rev)		 1.99 1.72 4.16 1.60 1.36 11.64 44.16 8.32 2.53 198.31 8.27
Enterprise Value to EBITDA (EV/EBITDA)		 114.55 0.00 168.27 0.00 0.00 377.74 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 158.23 0.00 179.81 0.00 0.00 388.68 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 181.94 0.00 186.38 0.00 0.00 393.08 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 53.01 0.00 0.00 382.47 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 54.55 0.00 0.00 495.93 0.00 17.32 0.38 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.28 0.00 0.11 0.00 -1.85 0.06
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.22 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.08 -1.07 -1.31 -1.25 -0.99 -0.88 -0.33 -0.25 -0.64 12.25 -0.47
Leverage Ratio		 1.96 2.07 2.12 1.79 1.78 2.21 1.42 1.48 2.77 -27.23 2.08
Compound Leverage Factor		 1.96 2.07 2.12 1.79 1.78 2.20 1.20 1.50 2.75 -27.38 2.24
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 21.81% 0.00% 10.23% 0.00% 217.55% 5.89%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 4.51% 0.00% 10.23% 0.00% 217.55% 5.89%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 17.30% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 78.19% 100.00% 89.77% 100.00% -117.55% 94.11%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 1.05 0.00 -0.08 0.00 -0.07 -0.03
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 -3.29 0.00 0.06 0.00 0.11 0.13
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.83 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 1.09 0.00 -0.11 0.00 -0.10 -0.08
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 -3.42 0.00 0.08 0.00 0.16 0.37
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.87 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 2.74 1.07 14.52 6.55 3.66 45.36 67.49 6.49 -43.02 -31.83 -18.00
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.10 1.75 2.02 2.62 1.89 1.91 3.47 0.72 0.89 0.53 1.43
Quick Ratio		 1.79 1.44 1.82 2.27 1.46 1.83 3.33 0.61 0.88 0.39 1.04
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -0.30 -0.12 0.81 -0.79 -0.72 0.33 -14 5.29 3.30 -7.58 -13
Operating Cash Flow to CapEx		 -1,453.55% -1,911.82% 99,531.79% -13,229.98% -10,960.16% 655.75% -1,053.72% -1,122.21% 0.00% -4,158.78% -6,401.56%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 104.46 0.00 64.85 0.00 0.00 -9.65
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 135.44 0.00 -73.68 0.00 0.00 -6.06
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 114.79 0.00 -80.25 0.00 0.00 -6.15
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 1.49 1.71 2.84 2.64 3.77 4.52 1.11 0.70 0.09 0.03 0.15
Accounts Receivable Turnover		 5.48 5.48 12.04 14.15 15.38 13.17 9.68 6.69 0.58 1.05 7.25
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 129.86 194.37 555.20 977.44 1,208.10 387.02 179.59 107.94 0.00 0.00 8.10
Accounts Payable Turnover		 79.28 86.40 170.24 186.18 72.58 73.11 30.28 13.33 0.00 0.00 0.31
Days Sales Outstanding (DSO)		 66.62 66.60 30.32 25.80 23.73 27.71 37.72 54.54 627.96 346.41 50.34
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 4.60 4.22 2.14 1.96 5.03 4.99 12.05 27.38 0.00 0.00 1,161.46
Cash Conversion Cycle (CCC)		 62.02 62.37 28.17 23.84 18.70 22.72 25.66 27.16 627.96 346.41 -1,111.12
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.01 -0.26 -0.84 -0.09 0.12 0.21 13 3.42 -2.03 -1.49 5.37
Invested Capital Turnover		 -35.48 -53.07 -19.34 -19.24 643.99 83.94 2.36 1.38 0.72 -0.06 0.59
Increase / (Decrease) in Invested Capital		 0.37 -0.27 -0.57 0.75 0.21 0.09 12 -9.09 -5.46 0.54 6.86
Enterprise Value (EV)		 12 12 44 14 14 162 664 92 1.26 21 9.45
Market Capitalization		 15 13 47 16 15 163 669 92 3.40 23 12
Book Value per Share		 $0.19 $0.15 $0.17 $0.17 $0.10 $0.14 $1.29 $0.19 $0.05 ($0.04) $0.61
Tangible Book Value per Share		 $0.19 $0.15 $0.17 $0.17 $0.10 $0.14 $0.13 $0.07 ($0.14) ($0.07) $0.13
Total Capital		 2.18 1.63 1.89 1.87 1.16 2.06 17 4.15 0.11 0.32 8.12
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.45 0.00 0.43 0.00 0.69 0.48
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.36 0.00 0.00 0.00 0.00 0.00
Net Debt		 -2.17 -1.90 -2.73 -1.96 -1.04 -1.41 -4.93 -0.31 -2.14 -1.12 -2.27
Capital Expenditures (CapEx)		 0.02 0.01 0.00 0.01 0.01 0.06 0.07 0.54 0.00 0.15 0.13
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.04 -0.30 -0.85 -0.10 0.00 -0.13 -0.04 -1.39 -2.42 -3.46 -1.06
Debt-free Net Working Capital (DFNWC)		 2.13 1.60 1.88 1.86 1.04 1.73 4.89 -0.66 -0.28 -1.65 1.69
Net Working Capital (NWC)		 2.13 1.60 1.88 1.86 1.04 1.64 4.89 -1.09 -0.28 -2.35 1.21
Net Nonoperating Expense (NNE)		 -0.01 0.16 -0.01 0.01 0.21 -0.00 -0.71 14 0.45 3.42 14
Net Nonoperating Obligations (NNO)		 -2.17 -1.90 -2.73 -1.96 -1.04 -1.41 -4.93 -0.31 -2.14 -1.12 -2.27
Total Depreciation and Amortization (D&A)		 0.03 0.03 0.02 0.01 0.01 0.01 0.86 0.40 0.00 0.07 0.30
Debt-free, Cash-free Net Working Capital to Revenue		 -0.63% -4.40% -8.03% -1.17% 0.03% -0.90% -0.27% -12.62% -485.94% -3,207.41% -92.91%
Debt-free Net Working Capital to Revenue		 34.26% 23.76% 17.64% 20.81% 10.25% 12.46% 32.54% -5.99% -55.62% -1,531.48% 147.64%
Net Working Capital to Revenue		 34.26% 23.76% 17.64% 20.81% 10.25% 11.79% 32.54% -9.85% -55.62% -2,174.07% 105.78%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.03 ($0.15) $0.06 $0.00 ($0.18) $0.12 ($0.27) ($2.94) ($3.12) ($1.60) ($1.97)
Adjusted Weighted Average Basic Shares Outstanding		 3.73M 3.73M 3.73M 3.73M 3.74M 3.74M 4.19M 6.02M 649.59K 6.55M 12.44M
Adjusted Diluted Earnings per Share		 $0.03 ($0.15) $0.06 $0.00 ($0.18) $0.09 ($0.27) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 3.77M 3.73M 3.86M 3.73M 3.74M 4.02M 4.19M 6.42M 671.06K 11.62M 14.79M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 3.73M 3.73M 3.73M 3.73M 3.74M 3.76M 0.00 6.42M 671.06K 11.62M 14.79M
Normalized Net Operating Profit after Tax (NOPAT)		 0.05 -0.39 0.17 -0.04 -0.51 0.29 -1.84 -3.79 -2.15 -6.43 -6.02
Normalized NOPAT Margin		 0.77% -5.86% 1.56% -0.49% -5.01% 2.07% -12.23% -34.41% -432.65% -5,950.00% -527.45%
Pre Tax Income Margin		 1.26% -8.23% 2.32% -0.57% -7.06% 2.97% -14.65% -49.84% -522.49% -9,683.33% -1,740.54%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 133.28 0.00 -66.30 0.00 0.00 -13.64
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 131.79 0.00 -46.47 0.00 0.00 -4.58
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 112.63 0.00 -72.87 0.00 0.00 -13.73
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 111.14 0.00 -53.04 0.00 0.00 -4.68
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Firefly Neuroscience

This table displays calculated financial ratios and metrics derived from Firefly Neuroscience's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 19,459,834.00 2,013,180.00 2,013,180.00 2,013,180.00 7,341,393.00 8,503,365.00 11,622,952.00 12,861,098.00 13,392,918.00 13,392,918.00 14,793,075.00
DEI Adjusted Shares Outstanding		 6,486,611.00 671,060.00 671,060.00 671,060.00 7,341,393.00 8,503,365.00 11,622,952.00 12,861,098.00 13,392,918.00 13,392,918.00 14,793,075.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.10 -1.25 -1.67 -1.88 -0.58 -0.45 -1.49 -0.14 -0.20 -0.20 -0.14
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -99.00% -364.28% -99.44% -99.51% 43.48% 101.43% 258.33% 2,890.00% 1,075.76% 677.36% 1,027.91%
EBITDA Growth		 54.01% -93.02% -28.92% -315.80% -464.24% -144.88% -909.29% -43.52% 38.95% 33.64% 82.61%
EBIT Growth		 42.59% -71.01% -17.32% -354.23% -558.89% -148.78% -922.23% -46.49% 37.65% 33.30% 82.44%
NOPAT Growth		 42.75% -121.87% -14.27% -278.72% -559.66% -74.47% -89.28% -29.79% 37.77% 27.21% 2.66%
Net Income Growth		 86.17% 91.13% 16.89% -638.36% -559.85% -351.76% -1,052.41% -45.02% 38.47% 34.48% 84.50%
EPS Growth		 0.00% 91.13% 0.00% 0.00% 0.00% -123.08% 0.00% 0.00% 67.21% 62.07% 0.00%
Operating Cash Flow Growth		 166.09% 44.18% 25.24% -182.39% -612.48% -138.82% -90.37% -117.47% 40.93% -48.19% 22.42%
Free Cash Flow Firm Growth		 196.61% -51.81% -101.37% -115.83% -123.99% -172.27% 3,521.78% -174.97% -192.18% -192.03% -353.53%
Invested Capital Growth		 -76.58% -159.41% -27.70% 0.00% -40.57% 26.70% -365.01% 364.14% 244.89% 460.03% 232.87%
Revenue Q/Q Growth		 -98.86% -16,229.33% 100.32% -16.67% 230.00% 60.61% -18.87% 595.35% 29.77% 6.19% 17.72%
EBITDA Q/Q Growth		 -230.31% -100.39% 25.96% -11.61% -240.72% 13.03% -205.18% 84.13% -44.93% 5.46% 20.02%
EBIT Q/Q Growth		 -231.17% -133.79% 25.96% -11.96% -239.95% 11.73% -204.25% 83.95% -44.69% 5.57% 19.88%
NOPAT Q/Q Growth		 -191.84% -204.39% 44.60% -15.40% -239.00% 19.49% 39.90% 20.87% -62.55% 5.84% 19.63%
Net Income Q/Q Growth		 -376.85% -28.90% -33.92% -12.66% -239.32% 11.75% -241.61% 85.82% -43.97% 6.03% 19.19%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 4.92% 0.00% 0.00% 0.00% -10.00% 0.00%
Operating Cash Flow Q/Q Growth		 226.30% -203.76% -158.63% 16.68% -129.21% 51.65% -106.16% 4.82% 37.74% -21.30% -7.92%
Free Cash Flow Firm Q/Q Growth		 -44.94% -49.35% -103.27% -1,638.17% 16.58% -52.59% 254.66% -239.68% 11.36% -52.51% -34.27%
Invested Capital Q/Q Growth		 0.00% -178.19% 180.88% -12.78% 7.74% -196.44% -192.42% 252.75% -19.94% 0.68% 7.92%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 91.64% 37.63% 44.17% 45.57%
EBITDA Margin		 -3,281.86% 0.00% -9,333.33% -12,500.00% -12,906.06% -6,988.68% -26,288.37% -600.00% -670.10% -596.60% -405.36%
Operating Margin		 -2,813.04% 0.00% -9,091.67% -12,590.00% -12,933.33% -6,483.02% -4,802.33% -546.49% -684.54% -607.04% -414.43%
EBIT Margin		 -2,813.04% 0.00% -9,333.33% -12,540.00% -12,918.18% -7,100.00% -26,625.58% -614.38% -685.05% -609.22% -414.64%
Profit (Net Income) Margin		 -2,826.09% 0.00% -9,350.00% -12,640.00% -12,996.97% -7,141.51% -30,069.77% -613.04% -680.15% -601.94% -413.20%
Tax Burden Percent		 100.00% 59.07% 100.00% 100.00% 100.00% 100.05% 100.00% 100.22% 100.00% 100.04% 100.00%
Interest Burden Percent		 100.46% 93.77% 100.18% 100.80% 100.61% 100.53% 112.94% 99.56% 99.29% 98.76% 99.65%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -1,774.79% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -40.45% -109.10% -250.33% -641.34%
ROIC Less NNEP Spread (ROIC-NNEP)		 -1,752.94% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -14.85% -81.02% -207.24% -631.55%
Return on Net Nonoperating Assets (RNNOA)		 203.92% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 5.93% 36.20% 96.60% 565.14%
Return on Equity (ROE)		 -1,570.87% 0.00% -116.43% -193.86% -265.44% 7,864.66% -646.06% -34.52% -72.90% -153.73% -76.21%
Cash Return on Invested Capital (CROIC)		 102.44% 0.00% -82.61% -684.56% -238.97% 0.00% 0.00% -326.31% -309.38% -243.26% -281.61%
Operating Return on Assets (OROA)		 -1,589.42% 0.00% 0.00% 0.00% 0.00% -211.76% -458.96% -28.82% -60.55% -92.28% -56.44%
Return on Assets (ROA)		 -1,596.79% 0.00% 0.00% 0.00% 0.00% -213.00% -518.32% -28.76% -60.12% -91.18% -56.25%
Return on Common Equity (ROCE)		 -1,570.87% 0.00% -116.43% -193.86% -265.44% 7,864.66% -646.06% -34.52% -72.90% -153.73% -76.21%
Return on Equity Simple (ROE_SIMPLE)		 -388.78% 0.00% -139.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -0.45 -1.38 -0.76 -0.88 -2.99 -2.41 -1.45 -1.14 -1.86 -1.75 -1.41
NOPAT Margin		 -1,969.13% 0.00% -6,364.17% -8,813.00% -9,053.33% -4,538.11% -3,361.63% -382.54% -479.18% -424.93% -290.10%
Net Nonoperating Expense Percent (NNEP)		 -21.84% 44.16% -450.69% 1,370.14% -172.01% -84.68% -239.05% -25.60% -28.08% -43.09% -9.79%
Return On Investment Capital (ROIC_SIMPLE)		 - -1,264.74% -34.58% -52.49% -107.62% -753.98% -27.88% -9.09% -19.25% -21.57% -15.77%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 8.36% 62.37% 55.83% 54.43%
SG&A Expenses to Revenue		 795.65% 0.00% 4,708.33% 6,260.00% 9,066.67% 3,679.25% 3,693.02% 459.20% 517.27% 485.44% 343.51%
R&D to Revenue		 1,704.35% 0.00% 2,408.33% 3,500.00% 2,660.61% 824.53% 725.58% 112.37% 97.42% 110.68% 87.42%
Operating Expenses to Revenue		 2,913.04% 0.00% 9,191.67% 12,690.00% 13,033.33% 6,583.02% 4,902.33% 638.13% 722.16% 651.21% 460.00%
Earnings before Interest and Taxes (EBIT)		 -0.65 -1.51 -1.12 -1.25 -4.26 -3.76 -11 -1.84 -2.66 -2.51 -2.01
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -0.75 -1.51 -1.12 -1.25 -4.26 -3.70 -11 -1.79 -2.60 -2.46 -1.97
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 17.44 31.21 4.08 3.02 8.04 0.00 6.45 3.01 4.04 1.53 3.82
Price to Tangible Book Value (P/TBV)		 70.86 0.00 0.00 0.00 13.39 0.00 6.66 6.25 10.87 7.32 13.20
Price to Revenue (P/Rev)		 8.14 6.83 0.00 0.00 0.00 208.65 240.42 85.04 49.77 10.26 20.36
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 19.23 0.00 4.20 2.94 13.64 0.00 0.00 4.65 6.50 1.76 5.11
Enterprise Value to Revenue (EV/Rev)		 8.10 2.53 0.00 0.00 0.00 198.31 171.75 72.33 44.25 8.27 18.69
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 7.12 0.38 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.21 0.00 0.29 0.22 0.00 -1.85 0.00 0.04 0.00 0.06 0.06
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.12 -0.64 -0.04 0.01 -0.27 12.25 -1.39 -0.40 -0.45 -0.47 -0.89
Leverage Ratio		 1.41 2.77 2.71 2.39 1.87 -27.23 2.34 1.35 1.43 2.08 1.71
Compound Leverage Factor		 1.42 2.59 2.71 2.41 1.88 -27.37 2.64 1.35 1.41 2.05 1.70
Debt to Total Capital		 17.08% 0.00% 22.64% 17.87% 0.00% 217.55% 0.00% 3.80% 0.00% 5.89% 5.36%
Short-Term Debt to Total Capital		 17.08% 0.00% 22.64% 17.87% 0.00% 217.55% 0.00% 3.80% 0.00% 5.89% 5.36%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 82.92% 100.00% 77.36% 82.13% 100.00% -117.55% 100.00% 96.20% 100.00% 94.11% 94.64%
Debt to EBITDA		 -0.29 0.00 -0.18 -0.06 0.00 -0.07 0.00 -0.02 0.00 -0.03 -0.05
Net Debt to EBITDA		 0.14 0.00 0.02 -0.01 0.00 0.11 0.00 0.26 0.00 0.13 0.30
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.40 0.00 -0.22 -0.09 0.00 -0.10 0.00 -0.06 0.00 -0.08 -0.08
Net Debt to NOPAT		 0.19 0.00 0.03 -0.02 0.00 0.16 0.00 0.68 0.00 0.37 0.43
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 4.95 -41.64 -12.15 -15.84 -19.98 -27.07 -11.77 -2.26 -4.17 -12.98 -6.98
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 1.25 0.89 0.76 0.61 1.05 0.53 1.45 2.69 2.00 1.43 1.82
Quick Ratio		 1.08 0.88 0.66 0.54 0.52 0.39 1.34 2.19 1.66 1.04 1.35
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 8.05 4.08 -0.13 -2.32 -1.93 -2.95 4.56 -6.37 -5.65 -8.61 -12
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% -1,717.19% -62,975.00% -1,522.50% -35,871.43% -19,916.67% -1,730.23% -7,847.83% -3,358.62%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 3.37 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -1.86 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -1.86 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.57 0.09 0.00 0.00 0.00 0.03 0.02 0.05 0.09 0.15 0.14
Accounts Receivable Turnover		 4.10 0.58 0.00 0.00 0.00 1.05 0.32 0.87 5.80 7.25 10.81
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 33.18 0.00 0.00 0.00 0.00 0.00 1.51 4.85 5.10 8.10 9.57
Accounts Payable Turnover		 11.80 0.00 0.00 0.00 0.00 0.00 0.00 0.02 0.20 0.31 0.52
Days Sales Outstanding (DSO)		 88.97 627.96 0.00 0.00 0.00 346.41 1,150.18 421.59 62.93 50.34 33.76
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 30.92 0.00 0.00 0.00 0.00 0.00 0.00 16,506.97 1,863.96 1,161.46 705.30
Cash Conversion Cycle (CCC)		 58.05 627.96 0.00 0.00 0.00 346.41 1,150.18 -16,085.39 -1,801.03 -1,111.12 -671.54
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 2.60 -2.03 1.65 1.43 1.55 -1.49 -4.36 6.66 5.33 5.37 5.79
Invested Capital Turnover		 0.90 0.72 0.00 0.00 0.00 -0.06 -0.10 0.11 0.23 0.59 2.21
Increase / (Decrease) in Invested Capital		 -8.51 -5.46 -0.63 1.43 -1.06 0.54 -6.01 5.23 3.79 6.86 10
Enterprise Value (EV)		 50 1.26 6.90 4.22 21 21 24 31 35 9.45 30
Market Capitalization		 50 3.40 6.97 4.17 22 23 33 36 39 12 32
Book Value per Share		 $0.15 $0.05 $0.85 $0.69 $0.38 ($0.04) $0.61 $0.94 $0.72 $0.61 $0.52
Tangible Book Value per Share		 $0.04 ($0.14) ($0.19) ($0.33) $0.23 ($0.07) $0.59 $0.45 $0.27 $0.13 $0.15
Total Capital		 3.48 0.11 2.21 1.68 2.78 0.32 5.19 13 9.66 8.12 8.92
Total Debt		 0.59 0.00 0.50 0.30 0.00 0.69 0.00 0.48 0.00 0.48 0.48
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -0.28 -2.14 -0.06 0.06 -1.23 -1.12 -9.55 -5.44 -4.33 -2.27 -2.65
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.06 0.00 0.08 0.01 0.01 0.09 0.02 0.06
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.25 -2.42 -0.54 -0.69 -1.10 -3.46 -6.35 -0.70 -1.61 -1.06 -0.64
Debt-free Net Working Capital (DFNWC)		 1.13 -0.28 0.02 -0.45 0.13 -1.65 3.20 5.21 2.71 1.69 2.49
Net Working Capital (NWC)		 0.54 -0.28 -0.48 -0.75 0.13 -2.35 3.20 4.74 2.71 1.21 2.01
Net Nonoperating Expense (NNE)		 0.20 -0.54 0.36 0.38 1.30 1.38 11 0.69 0.78 0.73 0.60
Net Nonoperating Obligations (NNO)		 -0.28 -2.14 -0.06 0.06 -1.23 -1.12 -9.55 -5.44 -4.33 -2.27 -2.65
Total Depreciation and Amortization (D&A)		 -0.11 0.00 0.00 0.00 0.00 0.06 0.15 0.04 0.06 0.05 0.05
Debt-free, Cash-free Net Working Capital to Revenue		 4.12% -485.94% 0.00% 0.00% 0.00% -3,207.41% -4,565.47% -164.49% -206.13% -92.91% -40.53%
Debt-free Net Working Capital to Revenue		 18.31% -55.62% 0.00% 0.00% 0.00% -1,531.48% 2,301.44% 1,218.22% 346.23% 147.64% 156.88%
Net Working Capital to Revenue		 8.70% -55.62% 0.00% 0.00% 0.00% -2,174.07% 2,301.44% 1,106.54% 346.23% 105.78% 126.70%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.24) ($0.78) ($0.99) ($0.58) ($0.61) ($0.58) ($1.74) ($0.14) ($0.20) ($0.22) ($0.13)
Adjusted Weighted Average Basic Shares Outstanding		 646.60K 1.08M 671.06K 671.06K 7.08M 6.55M 9.96M 12.67M 13.50M 12.44M 16.23M
Adjusted Diluted Earnings per Share		 $0.00 ($0.78) $0.00 ($0.58) $0.00 ($0.58) $0.00 $0.00 ($0.20) ($0.22) $0.00
Adjusted Weighted Average Diluted Shares Outstanding		 671.06K 671.06K 671.06K 671.06K 8.50M 11.62M 12.86M 13.39M 13.50M 14.79M 15.57M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($0.78) $0.00 $0.00 $0.00 ($0.58) $0.00 $0.00 $0.00 ($0.22) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 671.06K 671.06K 671.06K 7.34M 8.50M 11.62M 12.86M 13.39M 0.00 14.79M 15.57M
Normalized Net Operating Profit after Tax (NOPAT)		 -0.45 -1.38 -0.76 -0.88 -2.99 -2.41 -1.45 -1.14 -1.75 -1.75 -1.41
Normalized NOPAT Margin		 -1,969.13% 0.00% -6,364.17% -8,813.00% -9,053.33% -4,538.11% -3,361.63% -382.54% -451.75% -424.93% -290.10%
Pre Tax Income Margin		 -2,826.09% 0.00% -9,350.00% -12,640.00% -12,996.97% -7,137.74% -30,069.77% -611.71% -680.15% -601.70% -413.20%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -8.46 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -1.07 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -8.47 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -1.07 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Firefly Neuroscience (NASDAQ: AIFF) showed some encouraging revenue growth in Q1 2026, but the company remains deeply unprofitable and continues to rely on financing to support operations. Cash improved modestly during the quarter, yet the balance sheet and cash flow trends still point to a business that is burning cash faster than it is generating it.

  • Revenue grew year over year. Q1 2026 revenue rose to $485,000 from $412,000 in Q4 2025 and $43,000 in Q1 2025, showing continued top-line improvement.
  • Gross profit remained positive. The company generated $221,000 in gross profit in Q1 2026, indicating that core revenue is at least covering direct costs.
  • Cash increased sequentially. Cash and equivalents rose to $3.13 million at the end of Q1 2026, up from $3.08 million in Q4 2025.
  • Financing inflows supported liquidity. AIFF generated $2.39 million in net financing cash flow in Q1 2026, which helped offset operating losses and modest investing outflows.
  • Operating expenses improved from the prior quarter. Total operating expenses fell to $2.23 million in Q1 2026 from $2.68 million in Q4 2025, suggesting some cost discipline.
  • Revenue remains very small relative to expenses. Even with higher sales, quarterly revenue of $485,000 is still far below quarterly operating expenses.
  • Short-term debt was reduced. Short-term debt declined to $478,000 from $478,000 in Q4 2025 and was higher in earlier periods, so leverage is not the immediate issue, but it remains on the books.
  • Operating losses remain large. Q1 2026 operating loss was $2.01 million, and net loss was $2.00 million, showing the business is still far from break-even.
  • Operating cash flow was negative. The company used $1.95 million in operating cash during Q1 2026, so the core business is still consuming cash.
  • Equity financing appears necessary. The balance sheet and cash flow history suggest Firefly Neuroscience is relying on outside funding to keep operating, which can dilute shareholders over time.

Longer-term trend: Firefly Neuroscience has meaningfully improved revenue from the very low levels seen in early 2024, but losses have remained substantial across the last four years of data. The company’s cash position can swing significantly quarter to quarter depending on financing activity, while operating cash flow has generally stayed negative. That makes execution on revenue growth and expense control the key variables investors should watch.

Bottom line: AIFF is showing early signs of top-line momentum, but it is still a high-risk, cash-burning company. Until revenue scales much faster and operating losses narrow more materially, the investment case will likely depend heavily on future financing and execution.

07/28/26 06:09 PM ETAI Generated. May Contain Errors.

Firefly Neuroscience Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Firefly Neuroscience's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Firefly Neuroscience's net income appears to be on an upward trend, with a most recent value of -$19.88 million in 2025, falling from $78.33 thousand in 2015. The previous period was -$10.46 million in 2024. See Firefly Neuroscience's forecast for analyst expectations on what's next for the company.

Firefly Neuroscience's total operating income in 2025 was -$8.86 million, based on the following breakdown:
  • Total Gross Profit: $645 thousand
  • Total Operating Expenses: $9.50 million

Over the last 10 years, Firefly Neuroscience's total revenue changed from $6.21 million in 2015 to $1.14 million in 2025, a change of -81.6%.

Firefly Neuroscience's total liabilities were at $2.84 million at the end of 2025, a 42.9% decrease from 2024, and a 46.4% increase since 2015.

In the past 10 years, Firefly Neuroscience's cash and equivalents has ranged from $731.08 thousand in 2022 to $4.93 million in 2021, and is currently $2.75 million as of their latest financial filing in 2025.

Over the last 10 years, Firefly Neuroscience's book value per share changed from 0.19 in 2015 to 0.61 in 2025, a change of 215.7%.


Related Companies

Financial statements for NASDAQ:AIFF last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
3 Signs of The Biggest “Melt-Up” in U.S. History
In 1995, a convergence of three economic triggers fueled the biggest market melt-up in U.S. history. One self-...
True Market Insiders | Sponsoredtc pixel
ALT SL: New Patent Reveals Elon Musk’s Next Breakthrough: M.A.G.I.
Jeff Brown and Marc Chaikin - two investors who spotted Nvidia a decade ago - are now pointing to Elon Musk's ...
Brownstone Research | Sponsoredtc pixel
Trump’s $250 Bill – See Immediately
Former Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...
Stansberry Research | Sponsoredtc pixel
Three oil giants buried the same discovery for 50 years
In 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...
Behind the Markets | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
How to get a stake in Anthropic — before the IPO
Anthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...
Weiss Ratings | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
What's the Best Way to Lower RMD Taxes?
Once you turn 73, the IRS requires you to take distributions from your IRA, 401(k), and other retirement accou...
SmartAsset | Sponsoredtc pixel